Establishment of a human pancreatic tumor xenograft model: Potential application for preclinical evaluation of novel therapeutic agents

Pancreas

Volumn 16, Issue 1, 1998, Pages 19-25

  Mohammad, Ramzi M ^a   Dugan, Michael C ^b   Mohamed, Anwar N ^b   Almatchy, Victor P ^a   Flake, Thomas M ^b   Dergham, Sanaa T ^b   Shields, Anthony F ^a   Al Katib, Ayad A ^a   Vaitkevicius, Vainutis K ^a   Sarkar, Fazlul H ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Bryostatin 1; Cytarabine; Gemcitabine; KCI MOH1; Pancreatic tumor line; SCID mice; Taxol; Xenograft

Indexed keywords

BRYOSTATIN 1; CYTARABINE; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PROTEIN P21; PROTEIN P53;

ADENOCARCINOMA; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER SURVIVAL; CASE REPORT; CHROMOSOME ABERRATION; CLONAL ANERGY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOGENETICS; HUMAN; KARYOTYPE; MALE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0031962146     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-199801000-00004     Document Type: Conference Paper

References (23)

1. Wingo PA, Tang T, Bolden S. Cancer statistics, 1995. CA 1995; 45:8-30.
2. Gudjonnson B. Carcinoma of the pancreas. 50 years of surgery. Cancer 1987;60:2284-303.
3. Warshaw AW, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
4. Casper ES, Kelsen DP. Adenocarcinoma of the pancreas: overview of workup and management. Adv Oncol 1995;11:17-22.
5. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6:19-28.
6. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the anti-tumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-22.
7. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and anti-tumor activity of 2′-2′-difluorodeoxycytidine (gemcitabine). Cancer Invest 1990;8:313-8.
8. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
9. Hornung RL, Pearson JW, Beckwith M, Longo DL. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992;52:101-7.
10. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 1994;54:165-8.
11. Al-Katib AM, Mohammad RM, Hamdan M, et al. Propagation of Waldenstrom macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood 1993;81:3034-42.
12. Mohammad RM, Al-Katib A, Pettit GR, Sensenbrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leukemia Res 1993;17:1-8.
13. Dexler HG, Gignac SM, Jones RA, Scott CS, Pettit GR, Hoffbrand AV. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989;74:1747-57.
14. Pettit GR, Srirangam JK, Barkoczy J, et al. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Design 1995;10:529-44.
15. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. Isolation and structure of Bryostatin 1. J Am Chem Soc 1982; 104:6846-8.
16. Chopra DP, Grignon DJ, Joiakim A, et al. Differential growth factor responses of epithelial cell cultures derived from normal human prostate, benign prostatic hyperplasia and primary prostate carcinoma. J Cell Physiol 1996;169:269-80.
17. Mohamed AN, Wolman SR. Chromosome analysis in cell culture. In: Studzinski G, ed. Cell growth and apoptosis; a practical approach, vol 2, 2nd ed. New York: Oxford University Press, 1995: 79-96.
18. Mitelman F (ed). An international system for human cytogenetic nomenclature. Basel: Karger, 1995.
19. Chen YQ, Cipriano SC, Arenkiel JM, Miller FR. Tumor suppression by p21 WAF1. Cancer Res 1995;55:4536-9.
20. Chen YQ, Cipriano SC, Sarkar FH, et al. P53-independent induction of p21 WAF1 pathway is preserved during tumor progression. Int J Oncol 1995;7:889-93.
21. Corbett TH, Valeriote FA, Polin L, et al. Discovery of solid tumor activity agents using a soft-agar-colony-formation disk-diffusion-assay. In: Cytotoxic anti-cancer drugs: models and concepts for drug discovery and development. Boston: Kluwer Academic, 1992:35-89.
22. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD. Successful treatment of murine melanoma with bryostatin 1. Cancer Res 1991;51:682-7.
23. Kennedy MJ, Prestigiacomo LJ, Tyler G, et al. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 1992;52:1278-83.